Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its lead product candidates bavituximab and Cotara®. Bavituximab and Cotara are both in Phase II clinical studies for the treatment of cancer. In addition, bavituximab is also in a Phase I clinical study for the treatment of HCV infection. The Company also provides comprehensive biomanufacturing services for both Peregrine and outside customers through its wholly-owned subsidiary, Avid Bioservices, Inc.